| Market Cap | 12.92M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -13.5M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 3.00% |
| Sales | 635.45k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -18.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -86.00% |
| Recommedations | - | Quick Ratio | 0.00 | Shares Outstanding | 6.15B | 52W Low Chg | 110.00% |
| Insider Own | 82.61% | ROA | -191.54% | Shares Float | 1.07B | Beta | 20.13 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00210 |
| Gross Margin | 61.41% | Profit Margin | - | Avg. Volume | 1,811,905 | Target Price | - |
| Oper. Margin | -1,842.86% | Earnings Date | May 1 | Volume | 9,976,065 | Change | 5.00% |
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of oncology products in the United States. The company offers patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It also provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments. In addition, the company's data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. The company was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. Theralink Technologies, Inc.is headquartered in Golden, Colorado.
